2020-02-19T18:08:38+08:002018-02-08|News and events, Seminars and Workshops|
Talk title Infection and Immunity in ARDS: Novel Therapeutic Targets
Speaker Prof. Haibo ZHANG
Scientist, Keenan Research Centre for Biomedical Science of St. Michael’s Hospital;
Professor of Anesthesia, Medicine and Physiology, University of Toronto
Date & Time 8 February 2018 (Thursday) 10:00-11:00
Venue Room G004, E12 Building (University of Macau)
Abstract Acute respiratory distress syndrome (ARDS) constitutes a syndrome of acute hypoxemic respiratory failure that develops primarily from disruption of lung endothelial and epithelial integrity associated with excessive inflammatory responses. ARDS has a mortality rate of 30 – 40%. Multiple factors including pulmonary and extrapulmonary sepsis account for 75% of all predisposing causes of ARDS. Despite five decades of research, there is no proven pharmacological therapy for ARDS, and management remains supportive. Given the heterogeneity of ARDS, identification of ARDS endotypes may facilitate focusing on therapeutic interventions in the cohorts of patients who are most likely to benefit. Alternatively, novel therapeutics that target multiple mechanisms of injury, maintain or augment host defenses to pathogens, and facilitate the lung repair process are promising.